RxDoctor Payments Data

Kashish Goel

Interventional Cardiology · Nashville, TNNPI 1194046656

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $488,042 of the $557,699 with a category attached, or 87.5%. Edwards Lifesciences accounts for 92.4% of it on its own, with 7 other manufacturers making up the rest. Among interventional cardiology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$557,699in general payments, 2019–2025

Across 459 payments — averaging $1215.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$516K
  • Abbott$26K
  • Medtronic$11K
  • Boston Scientific$2K
  • Arrow International, Inc.$1K
  • Teleflex LLC$1K
  • plus $173 from 2 others
$559,811in research payments, 2019–2025

Across 88 payments — averaging $6361.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$243K
  • Medtronic$221K
  • Arrow International, Inc.$51K
  • Edwards Lifesciences$30K
  • Essential Medical, Inc.$15K

What the payments were for

  • Consulting fees$488,04288%
  • Speaking & faculty fees$2,3750%
  • Grants$2220%
  • Travel & lodging$55,99410%
  • Food & beverage$11,0662%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$557,699 in reported general payments places this provider in the 95th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$276,003
Medicare patients
500
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan43$61,279
EliquisApixaban42$51,096
JardianceEmpagliflozin25$37,844
Repatha SureclickEvolocumab33$31,085
FarxigaDapagliflozin Propanediol22$30,251
XareltoRivaroxaban14$19,559
Ranolazine ErRanolazine28$5,112
Praluent PenAlirocumab11$4,914
Isosorbide Mononitrate ErIsosorbide Mononitrate89$1,558
Atorvastatin Calcium116$1,141
Metoprolol Succinate72$834
ClopidogrelClopidogrel Bisulfate64$721
Amiodarone Hcl18$601
Potassium Chloride34$600
Prasugrel Hcl13$596

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →